ORKA Oruka Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| R&D expense | $100.64M | $1.01M |
| SG&A expense | $21.41M | $6.28M |
| Operating income | -$122.05M | -$7.30M |
| Pretax income | -$105.43M | — |
| Income tax | — | $0 |
| Net income | -$105.43M | -$5.34M |
| EBITDA | -$121.97M | -$7.28M |
| EPS (basic) | — | -0.37 |
| EPS (diluted) | — | -0.37 |
| Weighted avg. shares (diluted) | — | 14.42M |
| Balance sheet | ||
| Cash & equivalents | $46.94M | $37.43M |
| Short-term investments | $290.11M | — |
| Current assets | $343.86M | $37.59M |
| PP&E, net | $288,000 | $10,000 |
| Total assets | $488.62M | $37.86M |
| Current liabilities | $15.37M | $637,000 |
| Total liabilities | $16.69M | $841,000 |
| Shareholders' equity | $471.93M | $37.02M |
| Shares outstanding | 48.72M | 14.50M |
| Cash flow statement | ||
| Operating cash flow | -$88.21M | -$5.01M |
| Capital expenditure | $209,000 | $0 |
| Free cash flow | -$88.42M | -$5.01M |
| Investing cash flow | -$96.75M | $0 |
| Financing cash flow | $170.31M | $0 |
| Depreciation & amortization | $83,000 | $15,000 |
| Stock-based compensation | $24.24M | $686,000 |
Free plan shows the latest 2 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.